Biodesix Reports 42% Revenue Growth to $25.6 Million in Q1 2026

Biodesix, Inc. reported significant financial performance improvements in its quarterly filing for the period ending March 31, 2026. The company generated total revenues of $25.6 million, marking a 42% increase from $18.0 million in the same period last year. This growth was primarily driven by a 37% rise in Diagnostic Tests revenue, which reached $22.3 million, attributed to a 29% increase in test volumes to 17,800 and enhanced average revenue per test. Development Services revenue also saw a substantial increase of 99%, totaling $3.3 million, as a result of executing existing contracts and securing new agreements.

In terms of profitability, Biodesix reported a net loss of $7.8 million for the first quarter of 2026, a 30% improvement compared to a net loss of $11.1 million in the prior year. The company’s operating expenses, excluding direct costs, rose to $27.6 million, an 18% increase year-over-year, primarily due to investments in sales, marketing, and general administrative functions to support revenue growth. The gross margin for the quarter was reported at 84%, which included a one-time recovery of $0.4 million related to previously paid sales and use taxes; excluding this item, the gross margin was 82%, reflecting a 300-basis-point improvement from the previous year.

Operationally, Biodesix has made strategic advancements, including the expansion of its sales team and enhancements to its revenue cycle management processes. The company continues to focus on its core diagnostic testing services, which include five blood-based tests for lung disease, and has emphasized the importance of payer coverage in driving revenue growth. The company’s cash and cash equivalents increased by 35% to $25.6 million compared to the end of 2025, bolstered by $17.2 million raised through its at-the-market program.

Looking ahead, Biodesix remains optimistic about its growth trajectory, with plans to continue investing in research and development to innovate and expand its product offerings. The company is also focused on maintaining and expanding relationships with biopharmaceutical customers, which are critical for its Development Services segment. However, management acknowledged ongoing risks, including the need for sustained reimbursement from third-party payers and the potential impact of market conditions on its operations. The company’s outlook suggests a commitment to leveraging its diagnostic capabilities to improve patient care while navigating the complexities of the healthcare landscape.